Clinical Trial Update: A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating centanafadine sustained-release tablets for ADHD has completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Centanafadine sustained-release tablets (centanafadine)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder | Phase 3 | Status: COMPLETED | Results posted: 2021-05-05